Related Experiment Videos

Alloimmunization by hr'(c), hemolytic disease of newborns, and perinatal management

Insights

Hemolytic disease of the newborn due to anti-c alloimmunization affects many infants, with up to 40% requiring transfusions. Early detection via maternal antibody titers and amniotic fluid analysis aids in managing this condition.

Area of Science:

  • Obstetrics and Gynecology
  • Immunology
  • Neonatology

Background:

  • Anti-c alloimmunization is a significant concern in pregnancy, occurring almost as frequently as anti-D (Rh0).
  • Hemolytic disease of the newborn (HDN) can arise from maternal anti-c antibodies, impacting fetal health.

Purpose of the Study:

  • To investigate the natural history of hr'(c) hemolytic disease.
  • To establish management criteria for anti-c alloimmunization during pregnancy.

Main Methods:

  • Analysis of serologic evidence in infants born to c-alloimmunized women.
  • Correlation of maternal antiglobulin titers with disease severity.
  • Evaluation of factors like ABO incompatibility and maternal transfusion history.

Main Results:

  • 74% of infants from c-alloimmunized mothers and c-positive fathers show serologic evidence of HDN.
  • Up to 40% of affected infants necessitate transfusions.
  • Maternal antiglobulin titers < 1:16 generally indicate mild or no disease.

Conclusions:

  • Anti-c alloimmunization presents a notable risk for hemolytic disease of the newborn.
  • Maternal antibody titers and fetal antigen status guide management decisions.
  • Amniotic fluid pigment analysis is recommended for high-risk pregnancies.

Related Concept Videos